Show simple item record

dc.contributor.author Matei, Petru
dc.date.accessioned 2022-06-15T10:48:46Z
dc.date.available 2022-06-15T10:48:46Z
dc.date.issued 2022
dc.identifier.citation MATEI, Petru. Medicines used in tuberculosis therapy. In: MedEspera: the 9th International Medical Congress for Students and Young Doctors: abstract book. Chișinău: S. n., 2022, p. 318. en_US
dc.identifier.uri https://medespera.asr.md/en/books
dc.identifier.uri http://repository.usmf.md/handle/20.500.12710/21132
dc.description.abstract Introduction. In 2020, an estimated 10 million people fell ill with tuberculosis (TB) worldwide. Tuberculosis is a disease caused by the infection with the bacillus Mycobacterium tuberculosis, also called Koch Bacillus (BK). Tuberculosis is transmitted through the air from one person to another therefore it most commonly affects the lungs but also can attack other parts of the body, such as the kidney, spine, and brain. Nowadays, TB, including its drug-resistant forms, continues to be the main health problem in the world. The treatment of tuberculosis relies on several antituberculosis drugs administered in combination to achieve medicines synergy and to prevent drug resistance. New antituberculosis drugs and regimens are urgently needed to improve cure rates for people with drug resistant TB (currently around 50% globally). Aim of study. The research is aimed to analyze bibliographic data of antitubercular drugs used as first-line and second-line medicines to find alternative drugs. Methods and materials. Theoretic systemic research, dates and information analysis based on international facts: PubMed, Medline, Environmental Issues & Policy Index, Google Academic etc. Results. TB can be cured with the first-line drugs combination taken daily for several months such as: Isoniazid (isonicotinic acid hydrazide, or INH with a structural similarity to that of pyridoxine), Pyrazinamide (a synthetic analogue of nicotinamide), Rifampicin (a semisynthetic macrocyclic antibiotic with a large lipid-soluble molecule produced from Streptomyces mediterranei), Ethambutol (a watersoluble, heat-stable compound) and Streptomycin (an aminoglycoside antibiotic). If the patients with tuberculosis are resistant to the combinations of the first-line drug or intolerant then it is necessary to turn to the combinations of second-line drugs, such as: Prothionamide, Ethionamide, Rifabutin, pAminosalicylic acid, Cycloserine, fluoroquinolones: Ofloxacin, Lomefloxacin, Levofloxacin; Kanamycin, Capreomycin. The second-line drugs are called reserve drugs treatment. The combinations of two-, three-, four- and five-medicines is used to achieve antitubercular medicines synergy, prevent drug resistance, provide more reliable control over the intake of medicines, reduce the risk of overdose and of individual anti-tuberculosis drugs, is convenient for use in the hospital and, especially, in outpatient settings. Conclusion. Unfortunately, second-line drugs may have more side effects than the second-line drugs. Thus, the notion of "quality of life", which is quite common and has shown practical value in various diseases, is being used to evaluate the effectiveness of tuberculosis treatment. en_US
dc.language.iso en en_US
dc.publisher Nicolae Testemitanu State University of Medicine and Pharmacy of the Republic of Moldova, Association of Medical Students and Residents en_US
dc.relation.ispartof MedEspera: The 9th International Medical Congress for Students and Young Doctors, May 12-14, 2022, Chisinau, Republic of Moldova en_US
dc.title Medicines used in tuberculosis therapy en_US
dc.type Other en_US


Files in this item

This item appears in the following Collection(s)

  • MedEspera 2022
    The 9th International Medical Congress for Students and Young Doctors, May 12-14, 2022

Show simple item record

Search DSpace


Advanced Search

Browse

My Account

Statistics